22.45 +0.53 (2.42%)
After hours: 5:49PM EST
|Bid||21.00 x 1300|
|Ask||22.45 x 900|
|Day's Range||21.46 - 21.95|
|52 Week Range||8.85 - 23.05|
|Beta (3Y Monthly)||0.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.08|
Codexis, Inc. (CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder. Nestlé Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. CDX-6114 is Codexis’ first internally developed biotherapeutic product candidate.
Codexis, Inc. (CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova® Tablets, a novel, once-daily treatment for overactive bladder. “Our CodeEvolver® technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment. This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis President and CEO John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing.
Codexis stock approached a breakout Tuesday after the biotech company struck a deal with Dow Jones giant Merck for its protein-engineering technology. The platform is called CodeEvolver.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
REDWOOD CITY, Calif., Feb. 04, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a.
Every investor in Codexis, Inc. (NASDAQ:CDXS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Codexis is on pace to become the first publicly-traded synthetic biology company to deliver consistent operating profits. Investors should take note.
In 2012 John Nicols was appointed CEO of Codexis Inc (NASDAQ:CDXS). First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap Read More...
Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 4 cents. Earnings, adjusted for stock option expense and non-recurring costs, were less than 1 cent on a per-share ...
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor